Guidelines on managing chronic suppurative lung disease (CSLD) and bronchiectasis (unrelated to cystic fibrosis [CF]) in Australian Indigenous children initiated in 20021 were extended to include Indigenous adults in 20082 and children and adults living in urban areas of Australia and New Zealand in 2010.3 Here, we present an updated guideline relevant for all sections of the community. The recommendations in this guideline are targeted principally to primary and secondary care, and are not intended for individualised specialist care. As with all guidelines, they are not a substitute for sound clinical judgement, particularly when investigating and treating such a phenotypically heterogeneous condition as bronchiectasis.4
- 1. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ; Working Group on Indigenous Paediatric Respiratory Health. Bronchiectasis in Indigenous children in remote Australian communities [position statement]. Med J Aust 2002; 177: 200-204. <MJA full text>
- 2. Chang AB, Grimwood K, Macguire G, et al. Management of bronchiectasis and chronic suppurative lung disease in Indigenous children and adults from rural and remote Australian communities [position statement]. Med J Aust 2008; 189: 386-393. <MJA full text>
- 3. Chang AB, Bell SC, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australian and New Zealand. A position statement from the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation. Med J Aust 2010; 193: 356-365. <MJA full text>
- 4. King PT, Holdsworth SR, Farmer M, et al. Phenotypes of adult bronchiectasis: onset of productive cough in childhood and adulthood. COPD 2009; 6: 130-136.
- 5. Ringshausen FC, de Roux A, Pletz MW, et al. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: a population-based study of disease burden and trends. PLOS One 2013; 8: e71109.
- 6. Martínez-García MA, de la Rosa Carillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 823-831.
- 7. Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Respir Med 2010; 104: 981-985.
- 8. Chang AB, Robertson CF, van Asperen PP, et al. A multicenter study on chronic cough in children: burden and etiologies based on a standardized management pathway. Chest 2012; 142: 943-950.
- 9. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136: 1521-1528.
- 10. Chang AB, Byrnes CA, Everard ML. Diagnosing and preventing chronic suppurative lung disease and bronchiectasis. Paediatr Respir Rev 2011; 12: 97-103.
- 11. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 610-620.
- 12. Chang AB, Bell SC, Torzillo PJ, et al; and the extended voting group. Clinical guideline. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Thoracic Society of Australia and New Zealand. http://www.thoracic.org.au/imagesDB/wysiwyg/BEposstatement_2014_revised_TSANZ_website_v3_wrFINAL.pdf (accessed Dec 2014).
- 13. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.